Ihuman Financials
IH Stock | USD 1.52 0.03 1.94% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 1.48 | 2.8169 |
|
|
The financial analysis of Ihuman is a critical element in measuring its lifeblood. Investors should not minimize Ihuman's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Cash And Equivalents |
|
Ihuman | Select Account or Indicator |
Understanding current and past Ihuman Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Ihuman's financial statements are interrelated, with each one affecting the others. For example, an increase in Ihuman's assets may result in an increase in income on the income statement.
Ihuman Stock Summary
Ihuman competes with Boqii Holding, Lixiang Education, Huize Holding, and Kuke Music. iHuman Inc. provides intellectual development products to individual users, kindergartens, and distributors in the Peoples Republic of China. The company was founded in 1996 and is based in Beijing, the Peoples Republic of China. Ihuman Inc operates under Education Training Services classification in the United States and is traded on New York Stock Exchange. It employs 1119 people.Specialization | Consumer Discretionary, Education & Training Services |
Instrument | USA Stock View All |
Exchange | New York Stock Exchange |
ISIN | US45175B1098 |
CUSIP | 45175B109 |
Location | China |
Business Address | Building B, Beijing, |
Sector | Hotels, Restaurants & Leisure |
Industry | Consumer Discretionary |
Benchmark | Dow Jones Industrial |
Website | www.ihuman.com |
Phone | 86 10 5780 6606 |
Currency | USD - US Dollar |
Ihuman Key Financial Ratios
Return On Equity | 0.15 | ||||
Profit Margin | 0.14 % | ||||
Operating Margin | 0.09 % | ||||
Price To Sales | 0.08 X | ||||
Revenue | 1.02 B |
Ihuman Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 168.3M | 1.0B | 1.1B | 1.3B | 1.5B | 945.7M | |
Other Current Liab | 880K | 90.1M | 104.7M | 118.8M | 438.0M | 459.9M | |
Net Debt | (104.9M) | (855.1M) | (821.1M) | (1.0B) | (1.2B) | (1.1B) | |
Retained Earnings | (348.5M) | (386.0M) | (423.0M) | (321.2M) | (140.5M) | (147.5M) | |
Accounts Payable | 10.3M | 21.6M | 30.5M | 24.2M | 22.1M | 22.3M | |
Cash | 104.9M | 861.7M | 855.4M | 1.0B | 1.2B | 750.2M | |
Other Assets | 2.7M | 784K | 7.8M | 6.4M | 7.4M | 4.0M | |
Net Receivables | 21.0M | 78.3M | 59.0M | 81.9M | 62.6M | 58.0M | |
Capital Surpluse | 213.1M | 1.1B | 1.1B | 1.1B | 1.2B | 751.9M | |
Inventory | 20.7M | 16.9M | 28.1M | 19.1M | 16.5M | 17.4M | |
Other Current Assets | 574K | 64.6M | 72.9M | 102.8M | 89.5M | 60.9M | |
Total Liab | 182.8M | 404.3M | 492.5M | 563.9M | 492.7M | 414.1M | |
Net Invested Capital | (14.4M) | 642.7M | 608.4M | 769.5M | 957.8M | 531.7M | |
Total Current Assets | 163.1M | 1.0B | 1.0B | 1.3B | 1.4B | 897.1M | |
Cash And Equivalents | 104.9M | 861.7M | 855.4M | 1.0B | 1.2B | 633.2M | |
Net Working Capital | (19.7M) | 622.2M | 532.3M | 692.7M | 891.7M | 486.6M | |
Short Term Debt | 99.8M | 1.5M | 24.7M | 6.1M | 1.9M | 1.8M | |
Intangible Assets | 103K | 11.8M | 27.3M | 24.9M | 23.2M | 16.0M |
Ihuman Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Tax Provision | 1.4M | 466K | (145K) | 23.0M | 33.1M | 34.8M | |
Interest Expense | 4.6M | 10.3M | 23.5M | 21.2M | 24.4M | 13.1M | |
Total Revenue | 218.7M | 531.9M | 944.7M | 985.5M | 1.0B | 702.3M | |
Gross Profit | 134.5M | 365.4M | 660.6M | 691.2M | 721.3M | 483.8M | |
Operating Income | (278.8M) | (44.5M) | (54.2M) | 111.6M | 159.9M | 167.9M | |
Ebit | (278.8M) | (44.5M) | (54.2M) | 111.6M | 159.9M | 167.9M | |
Research Development | 170.2M | 199.5M | 415.3M | 313.5M | 257.5M | 258.2M | |
Ebitda | (278.2M) | (41.6M) | (47.8M) | 122.4M | 171.6M | 180.2M | |
Cost Of Revenue | 84.2M | 166.5M | 284.1M | 294.3M | 296.9M | 218.5M | |
Income Before Tax | (274.2M) | (37.0M) | (37.2M) | 132.8M | 202.6M | 212.7M | |
Net Income | (275.6M) | (37.5M) | (37.1M) | 109.8M | 180.9M | 190.0M | |
Income Tax Expense | 1.4M | 466K | (145K) | 23.0M | 21.7M | 22.7M |
Ihuman Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change To Inventory | 8.9M | 2.2M | (12.6M) | 6.7M | 3.0M | 1.7M | |
Investments | (2.4M) | (15.9M) | (32.0M) | (32.8M) | (6.5M) | (6.8M) | |
Change In Cash | 98.8M | 756.8M | (6.3M) | 194.6M | 163.8M | 222.4M | |
Free Cash Flow | 40.2M | 207.1M | 5.9M | 181.9M | 165.6M | 109.2M | |
Depreciation | 597K | 2.8M | 6.4M | 10.8M | 11.7M | 6.0M | |
Other Non Cash Items | 249K | 11.3M | 21.8M | 28.8M | (52.1M) | (49.5M) | |
Capital Expenditures | 2.4M | 15.9M | 32.3M | 6.6M | 6.5M | 11.8M | |
Net Income | (275.6M) | (37.5M) | (37.1M) | 109.8M | 180.9M | 190.0M | |
End Period Cash Flow | 104.9M | 861.7M | 855.4M | 1.0B | 1.2B | 750.2M | |
Change To Netincome | 270.8M | 92.6M | 38.6M | 41.8M | 37.7M | 71.0M |
Ihuman Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ihuman's current stock value. Our valuation model uses many indicators to compare Ihuman value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ihuman competition to find correlations between indicators driving Ihuman's intrinsic value. More Info.Ihuman Inc is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers reporting about 0.31 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Ihuman Inc is roughly 3.24 . As of now, Ihuman's Return On Equity is increasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ihuman's earnings, one of the primary drivers of an investment's value.Ihuman Inc Systematic Risk
Ihuman's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Ihuman volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Ihuman Inc correlated with the market. If Beta is less than 0 Ihuman generally moves in the opposite direction as compared to the market. If Ihuman Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Ihuman Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Ihuman is generally in the same direction as the market. If Beta > 1 Ihuman moves generally in the same direction as, but more than the movement of the benchmark.
Ihuman Thematic Clasifications
Ihuman Inc is part of several thematic ideas from Railroads to Books. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasToday, most investors in Ihuman Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Ihuman's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Ihuman growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Ihuman November 24, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Ihuman help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Ihuman Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Ihuman Inc based on widely used predictive technical indicators. In general, we focus on analyzing Ihuman Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Ihuman's daily price indicators and compare them against related drivers.
Information Ratio | (0.04) | |||
Maximum Drawdown | 22.95 | |||
Value At Risk | (5.49) | |||
Potential Upside | 6.16 |
Complementary Tools for Ihuman Stock analysis
When running Ihuman's price analysis, check to measure Ihuman's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ihuman is operating at the current time. Most of Ihuman's value examination focuses on studying past and present price action to predict the probability of Ihuman's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ihuman's price. Additionally, you may evaluate how the addition of Ihuman to your portfolios can decrease your overall portfolio volatility.
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Stocks Directory Find actively traded stocks across global markets | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |